Aptevo Therapeutics宣布,Care Fund将为其Apvo451的IND申报前研究提供150万美元的资金支持。根据提交给美国证券交易委员会(SEC)的文件披露,这笔资金将专项用于推动该候选药物的临床前开发工作,以支持其后续向监管机构提交新药临床试验申请(IND)。
Apvo451是Aptevo公司正在开发的一款新型治疗性候选药物。获得此项资金将加速其临床前研究的进程,为后续进入临床试验阶段奠定基础。
Aptevo Therapeutics宣布,Care Fund将为其Apvo451的IND申报前研究提供150万美元的资金支持。根据提交给美国证券交易委员会(SEC)的文件披露,这笔资金将专项用于推动该候选药物的临床前开发工作,以支持其后续向监管机构提交新药临床试验申请(IND)。
Apvo451是Aptevo公司正在开发的一款新型治疗性候选药物。获得此项资金将加速其临床前研究的进程,为后续进入临床试验阶段奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.